The public markets have yet to fully recognize that Pfizer (PFE) has a nice recipe to win in oncology in its quest to cure cancer, the pharmaceutical company's president and general manager of global oncology told attendees of the UBS Global Healthcare Conference.
"I'm not sure we're getting credit for oncology yet at Pfizer," Liz Barrett said at the Grand Hyatt New York on Monday. "Ibrance, yes, but we have a broad portfolio."
Pfizer's therapy for metastatic breast cancer, Ibrance, has done tremendously well and has exceeded everyone's expectations since its launch about a year ago, Barrett said.
"I'm not sure we're getting credit for oncology yet at Pfizer," Liz Barrett said at the Grand Hyatt New York on Monday. "Ibrance, yes, but we have a broad portfolio."
Pfizer's therapy for metastatic breast cancer, Ibrance, has done tremendously well and has exceeded everyone's expectations since its launch about a year ago, Barrett said.
